Novartis will showcase data from 13 abstracts on fingolimod (Gilenya®) at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) meetings in Amsterdam this week.
The data being presented for fingolimod at ECTRIMS/ACTRIMS highlight the Novartis clinical trial program for sphingosine 1-phosphate receptor (S1PR) modulators.
Fingolimod targets MS via effects on the immune system and new pre-clinical data to be presented at ECTRIMS/ACTRIMS supports an additional potential direct effect on the central nervous system (CNS), although the clinical relevance of this remains to be determined.
Additional clinical data describe efficacy in subgroups of patients with highly active disease in the pivotal Phase III studies.
“Gilenya has already demonstrated significant efficacy in large scale clinical trials which is reinforced by these important data presented at ECTRIMS/ACTRIMS reflecting different patient populations in need of a new treatment,” said David Epstein, Head of the Pharmaceuticals Division at Novartis Pharma AG.
“These findings will help further solidify the role of Gilenya in the treatment of MS within its approved indication.”